Case Study · TrimRX · Incrementality
How We Proved CTV Drove Real, Incremental Revenue for TrimRX
TrimRX, a fast-growing GLP-1 telehealth brand, didn’t trust platform-reported ROAS to judge CTV. We built a 51-market synthetic difference-in-differences test to measure what CTV actually added to their bottom line.
Results at a glance
4.94%
Average weekly revenue lift from CTV
~9.4%
Peak weekly revenue lift (week of May 4)
3.42x
Incremental ROAS
p < 0.03
Statistical significance, with 6 of 7 weeks at p < 0.01
The Problem
Attribution takes credit. It doesn’t prove it.
TrimRX didn’t trust platform-reported ROAS or last-click attribution to judge CTV, and for good reason. Platforms overcount by crediting anyone who was merely exposed to an ad. In GLP-1 telehealth, where a patient might see a CTV spot, click a Meta ad days later, and then finish an intake form, that leaves the true impact of CTV unknown. TrimRX needed a number that could hold up to scrutiny and guide real budget decisions.
How it Works
How SDiD finds the lift attribution can’t
SDiD answers one question: what would have happened without CTV?
01
Turn it on in test markets
We turned CTV on in 16 test states and kept it off in the other 34 states and DC.
02
Build a synthetic twin
The model blends the untouched markets into a “synthetic” twin that tracks the test markets’ sales almost exactly before launch.
03
Measure the gap
After launch, the gap between the real test markets and their synthetic twin is the lift the channel caused.
Platform attribution
Credits touches, not causes
Measures first-party revenue and orders, not attributed conversions
Before/after comparison
Mixes in seasonality, promos, and site changes
Compares against markets living through the same calendar
Simple holdout (one test vs. one control market)
No two markets behave alike
Weights many control markets into a close-fitting twin
Our Method
How we run an SDiD test
Every test follows the same six steps, and the client signs off on the design before a dollar is spent.
01
Pull first-party data
We analyzed 19 weeks of weekly revenue and conversions by state from TrimRX’s own backend. Platform-reported conversions were never the outcome we measured.
02
Account for every other channel
TrimRX’s Meta and Google spend kept running at near-identical levels in test and control states, and went into the model as covariates. That left CTV as the only variable.
03
Pick the markets
An algorithm split all 51 markets into 16 test states and 35 control markets to maximize pre-test balance. The two groups were within 2% on weekly revenue and 1% on weekly conversions before launch.
04
Pre-test the model
All 8 statistical quality checks passed. Revenue and conversion trends correlated at 0.997 and 0.999, parallel-trend tests passed (p = 0.96 and p = 0.97), and week-to-week error against the benchmark was just 2.79% on revenue and 2.74% on conversions. A placebo check against 500 random market splits put our design in the bottom 8% for imbalance on revenue and the bottom 2% on conversions.
05
Run the full flight
CTV launched in the 16 test states on April 13, 2026, and ran for 7 weeks through June 1. Control markets ran no CTV.
06
Read it and act on it
We measured the lift every week against the synthetic twin, with confidence intervals and p-values, then rolled it up into incremental revenue, ROAS, conversions, and CPA.
Revenue and orders are modeled directly. Calculated metrics like AOV add noise, so we infer them from the core models rather than test them on their own.
Client Spotlight
TrimRX
TrimRX connects patients with licensed physicians for personalized GLP-1 weight-loss treatment, delivered to their door. With Meta and Google already running at scale, crediting CTV off platform attribution would have been easy to overstate, or to miss entirely.
The result
+4.94%
Average weekly revenue lift, positive in every one of the 7 weeks and peaking at about 9.4% the week of May 4. CTV delivered a 3.42x incremental ROAS, measured without platform attribution.
7 of 7
Weeks with positive revenue lift
3.42x
Incremental ROAS
Test design
We launched CTV through MNTN in 16 test states at a steady weekly budget and held it back in 35 control markets. Meta and Google spend continued at matched levels across both groups and went into the model as covariates. The outcome was first-party revenue, not view-through conversions.
What the Results Changed
CTV went from a question mark to a performance channel
Lift that kept growing
Cumulative incremental revenue rose every single week through week 7 with no sign of diminishing returns. That’s a strong signal CTV can scale.
Results you can trust
The 95% confidence interval stayed above zero the entire test. The lift was real, not noise.
A benchmark to defend
With true lift isolated, TrimRX can defend CTV spend, set a real efficiency target, and weigh it against every other channel on equal footing.
If your measurement lives inside the ad platform, the platform is grading its own homework. Attribution credits views. SDiD measures outcomes. The only way to know if CTV is working is to run markets where it isn’t.
Where SDiD Fits
Built for telehealth brands with real volume across many states
Telehealth brands are a natural fit for SDiD. They sell in many states at once, they own clean first-party order data, and they usually run several channels that all claim the same patient. If you’re licensed in enough states to hold some back, you can measure what a channel actually adds.
Is CTV driving sales, or just taking credit?
Measures CTV’s lift against first-party revenue
Which CTV partner performs better?
Runs two platforms in paired markets, head to head
Does CTV move in-store retail sales?
Tests regional markets against store-level sales data
Should we scale, and by how much?
Pairs the lift read with a diminishing-returns curve
Want to know what your CTV is really driving?
We’ll tell you up front if your brand has the volume and market spread for a clean test.